Page last updated: 2024-12-05

tele-methylhistamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

tele-methylhistamine: histamine methyltransferase antagonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

N(tele)-methylhistamine : A primary amino compound that is the N(tele)-methyl derivative of histamine. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID3614
CHEMBL ID507
CHEBI ID29009
SCHEMBL ID196356
SCHEMBL ID3826532
MeSH IDM0074072
PubMed CID11957601
CHEMBL ID1487156
SCHEMBL ID1320841
MeSH IDM0074072

Synonyms (113)

Synonym
5-25-09-00527 (beilstein handbook reference)
kcb81t4eof ,
unii-kcb81t4eof
gtpl1242
gtpl1241
n-[3h]methylhistamine
n(1)-methylhistamine
n(tele)-methylhistamine
2-(1-methyl-1h-imidazol-4-yl)ethanamine
CHEBI:29009 ,
1-methyl-4-(beta-aminoethyl)imidazole
1h-imidazole, 4-(1-aminoethyl)-1-methyl-
n(sup 1)-methylhistamine
nsc 66736
brn 0110757
1h-imidazole-4-ethanamine, 1-methyl-
1-methyl-4-(.beta.-aminoethyl)imidazole
nsc66736
nsc-66736
n.tau.-methylhistamine
1-methyl-4-histamine
n-telle-methylhistamine
imidazole, 4-(2-aminoethyl)-1-methyl-
NCGC00015677-01
lopac-m-4910
LOPAC0_000757
PDSP1_000511
n1-methylhistamine
1-methyl-4-(2-aminoethyl)imidazole
C05127
ntau-methylhistamine
tele-methylhistamine
1-methyl-1h-imidazole-4-ethanamine
501-75-7
1-methylhistamine
PDSP2_000509
NCGC00162240-01
histamine, 1-methyl-
AF9B9F65-564B-4C50-B4AF-F195114242DE
NCGC00015677-03
L000842
CHEMBL507
1-methyl-4-(b-aminoethyl)imidazole
AKOS006350836
2-(1-methylimidazol-4-yl)ethanamine
CCG-204842
NCGC00015677-02
FT-0608087
H137 ,
SCHEMBL196356
n-tele-methylhistamine
2-(1-methyl-1h-imidazol-4-yl)ethylamine
[2-(1-methyl-1h-imidazol-4-yl)ethyl]amine
SCHEMBL3826532
2-(1-methyl-1h-imidazol-4-yl)ethylamine #
4-(2-aminoethyl)-1-methylimidazole
2-(1-methyl-1h-imidazol-4-yl)ethan-1-amine
DTXSID30198207
n( 1)-methylhistamine
nt-methylhistamine
4-(2-aminoethyl)-1-methyl-imidazole
HY-W062542
bdbm50198912
CS-0054396
mfcd01941538
FT-0701318
AS-50436
Q27078070
SB15504
SDCCGSBI-0050735.P002
NCGC00015677-04
2-(1-methylimidazole-4-yl)ethanamine
P10213
EN300-116916
EU-0100757 ,
1-methylhistamine dihydrochloride, >=98% (tlc), powder
1-methylhistamine dihydrochloride
NCGC00094097-01
M 4910
6481-48-7
SCHEMBL1320841
1h-imidazole-4-ethanamine,1-methyl-
LP00757
AGXVEALMQHTMSW-UHFFFAOYSA-N
[2-(1-methyl-1h-imidazol-4-yl)ethyl]amine dihydrochloride
2(1-methyl-1h-imidazol-4-yl)-ethylamine bis hydrochloride
1-methyl-4-(2-aminoethyl)imidazole dihydrochloride
CHEMBL1487156
CCG-222061
AKOS016367671
tox21_500757
NCGC00261442-01
1-methyl-4-(beta-aminoethyl)imidazole dihydrochloride
mfcd00037000
2-(1-methyl-1h-imidazol-4-yl)ethanamine dihydrochloride
SR-01000075290-1
sr-01000075290
NS-01990
2-(1-methyl-1h-imidazol-4-yl)ethan-1-amine dihydrochloride
1-methylhistamine 2hcl
CS-0046885
1-methylhistamine (dihydrochloride)
DTXSID201017448
1-methyl-4-[beta-aminoethyl]imidazole dihydrochloride
A923730
2-(1-methylimidazol-4-yl)ethanamine;dihydrochloride
1-methylhistamine (hydrochloride)
W10018
methylhistamine dihcl
2-(1-methyl-1h-imidazol-4-yl)ethanaminedihydrochloride
HY-W053787
EN300-7399032
SY039437

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
", led to an oral bioavailability ratio of 62%."( Neurochemical and behavioral effects of ciproxifan, a potent histamine H3-receptor antagonist.
Elz, S; Ganellin, CR; Jouvet, M; Ligneau, X; Lin, J; Muir, JL; Schunack, W; Schwartz, J; Stark, H; Vanni-Mercier, G, 1998
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
imidazolesA five-membered organic heterocycle containing two nitrogen atoms at positions 1 and 3, or any of its derivatives; compounds containing an imidazole skeleton.
primary amino compoundA compound formally derived from ammonia by replacing one hydrogen atom by an organyl group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (9)

PathwayProteinsCompounds
Metabolism14961108
Amino acid and derivative metabolism250260
Histidine, lysine, phenylalanine, tyrosine, proline and tryptophan catabolism4485
Histidine catabolism822
Histidine Metabolism1735
Histidinemia1735
Histidine degradation ( Histidine degradation )2326
Histidine metabolism120
Biochemical pathways: part I0466
Amino acid metabolism094

Protein Targets (11)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
thioredoxin reductaseRattus norvegicus (Norway rat)Potency0.44670.100020.879379.4328AID588453
thyroid stimulating hormone receptorHomo sapiens (human)Potency6.30960.001318.074339.8107AID926
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency7.94330.035520.977089.1251AID504332
cytochrome P450 2C19 precursorHomo sapiens (human)Potency39.81070.00255.840031.6228AID899
cytochrome P450 2C9 precursorHomo sapiens (human)Potency39.81070.00636.904339.8107AID883
serine/threonine-protein kinase mTOR isoform 1Homo sapiens (human)Potency3.28850.00378.618923.2809AID2668
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency39.81070.00638.235039.8107AID883
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency0.00540.060110.745337.9330AID485368
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency0.00710.004023.8416100.0000AID485290
thioredoxin reductaseRattus norvegicus (Norway rat)Potency23.77810.100020.879379.4328AID588453
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency0.02240.035520.977089.1251AID504332
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Histamine H4 receptorHomo sapiens (human)Ki11.00000.00060.478710.0000AID1323898
Histamine H3 receptorHomo sapiens (human)Ki20.00000.00010.33998.5110AID1323901
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (9)

Processvia Protein(s)Taxonomy
inflammatory responseHistamine H4 receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationHistamine H4 receptorHomo sapiens (human)
biological_processHistamine H4 receptorHomo sapiens (human)
regulation of MAPK cascadeHistamine H4 receptorHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayHistamine H4 receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayHistamine H4 receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerHistamine H4 receptorHomo sapiens (human)
chemical synaptic transmissionHistamine H4 receptorHomo sapiens (human)
neurotransmitter secretionHistamine H3 receptorHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayHistamine H3 receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerHistamine H3 receptorHomo sapiens (human)
chemical synaptic transmissionHistamine H3 receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayHistamine H3 receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (3)

Processvia Protein(s)Taxonomy
histamine receptor activityHistamine H4 receptorHomo sapiens (human)
G protein-coupled serotonin receptor activityHistamine H4 receptorHomo sapiens (human)
G protein-coupled acetylcholine receptor activityHistamine H4 receptorHomo sapiens (human)
histamine receptor activityHistamine H3 receptorHomo sapiens (human)
G protein-coupled acetylcholine receptor activityHistamine H3 receptorHomo sapiens (human)
G protein-coupled serotonin receptor activityHistamine H3 receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
plasma membraneHistamine H4 receptorHomo sapiens (human)
plasma membraneHistamine H4 receptorHomo sapiens (human)
dendriteHistamine H4 receptorHomo sapiens (human)
synapseHistamine H4 receptorHomo sapiens (human)
plasma membraneHistamine H3 receptorHomo sapiens (human)
presynapseHistamine H3 receptorHomo sapiens (human)
plasma membraneHistamine H3 receptorHomo sapiens (human)
synapseHistamine H3 receptorHomo sapiens (human)
dendriteHistamine H3 receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (50)

Assay IDTitleYearJournalArticle
AID1323898Binding affinity to histamine H4 receptor (unknown origin)2016Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21
Synthesis and evaluation of a 2-benzothiazolylphenylmethyl ether class of histamine H4 receptor antagonists.
AID157860In vitro antimalarial activity against chloroquine-sensitive Plasmodium falciparum2002Bioorganic & medicinal chemistry letters, Jul-08, Volume: 12, Issue:13
Antimalarial activities of ring-substituted bioimidazoles.
AID183687Relative inhibition of [3H]histamine release from pre-loaded slices of rat cerebral cortex1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Histamine H3 ligands: just pharmacological tools or potential therapeutic agents?
AID72703In vitro inotropy blocking studies in ferret papillary muscle in the presence of 10 uM cimetidine; B-Blocked1990Journal of medicinal chemistry, Jun, Volume: 33, Issue:6
Cardiotonic agents. 6. Histamine analogues as potential cardiovascular selective H2 agonists.
AID78483In vitro contractile response of histamine at 0.5 ug/mL in guinea pig ileum1990Journal of medicinal chemistry, Jun, Volume: 33, Issue:6
Cardiotonic agents. 6. Histamine analogues as potential cardiovascular selective H2 agonists.
AID86257Evaluated for activity at Histamine H1 receptor in guinea pig ileum1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Histamine H3 ligands: just pharmacological tools or potential therapeutic agents?
AID78482In vitro chronotropic effect of histamine at 5 ug/mL in guinea pig atrium1990Journal of medicinal chemistry, Jun, Volume: 33, Issue:6
Cardiotonic agents. 6. Histamine analogues as potential cardiovascular selective H2 agonists.
AID72705In vitro inotropy blocking studies in ferret papillary muscle in the presence of 100 uM nadolol; NB-Not Blocked1990Journal of medicinal chemistry, Jun, Volume: 33, Issue:6
Cardiotonic agents. 6. Histamine analogues as potential cardiovascular selective H2 agonists.
AID1323901Binding affinity to histamine H3 receptor (unknown origin)2016Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21
Synthesis and evaluation of a 2-benzothiazolylphenylmethyl ether class of histamine H4 receptor antagonists.
AID72706Concentration of compound which gives 20% increase in the force contraction in ferret papillary muscle.1990Journal of medicinal chemistry, Jun, Volume: 33, Issue:6
Cardiotonic agents. 6. Histamine analogues as potential cardiovascular selective H2 agonists.
AID87852Evaluated for activity at Histamine H2 receptor in guinea pig ileum1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Histamine H3 ligands: just pharmacological tools or potential therapeutic agents?
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1346028Rat H4 receptor (Histamine receptors)2001The Journal of pharmacology and experimental therapeutics, Oct, Volume: 299, Issue:1
Comparison of human, mouse, rat, and guinea pig histamine H4 receptors reveals substantial pharmacological species variation.
AID1346055Human H4 receptor (Histamine receptors)2006British journal of pharmacology, Apr, Volume: 147, Issue:7
Compared pharmacology of human histamine H3 and H4 receptors: structure-activity relationships of histamine derivatives.
AID1346107Human H3 receptor (Histamine receptors)2001The Biochemical journal, Apr-15, Volume: 355, Issue:Pt 2
Genomic organization and characterization of splice variants of the human histamine H3 receptor.
AID1346017Rat H3 receptor (Histamine receptors)2000The Journal of pharmacology and experimental therapeutics, Jun, Volume: 293, Issue:3
Cloning of rat histamine H(3) receptor reveals distinct species pharmacological profiles.
AID1346055Human H4 receptor (Histamine receptors)2001Molecular pharmacology, Mar, Volume: 59, Issue:3
Cloning and pharmacological characterization of a fourth histamine receptor (H(4)) expressed in bone marrow.
AID1346044Mouse H4 receptor (Histamine receptors)2001The Journal of pharmacology and experimental therapeutics, Oct, Volume: 299, Issue:1
Comparison of human, mouse, rat, and guinea pig histamine H4 receptors reveals substantial pharmacological species variation.
AID1346107Human H3 receptor (Histamine receptors)2001Molecular pharmacology, Mar, Volume: 59, Issue:3
Cloning and pharmacological characterization of a fourth histamine receptor (H(4)) expressed in bone marrow.
AID1346055Human H4 receptor (Histamine receptors)2001The Journal of pharmacology and experimental therapeutics, Oct, Volume: 299, Issue:1
Comparison of human, mouse, rat, and guinea pig histamine H4 receptors reveals substantial pharmacological species variation.
AID1346107Human H3 receptor (Histamine receptors)2000The Journal of pharmacology and experimental therapeutics, Jun, Volume: 293, Issue:3
Cloning of rat histamine H(3) receptor reveals distinct species pharmacological profiles.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1148743Retardation factor of the compound using MeOH-NH4OH-H2O at ratio of 6:1:1 as solvent system by thin layer chromatography1976Journal of medicinal chemistry, Jul, Volume: 19, Issue:7
Potential histamine H2-receptor antagonists. 3. Methylhistamines.
AID1148741Retardation factor of the compound using EtOCH2CH2OH-HCl(11N)-H2O at ratio of 8:1:1 as solvent system by thin layer chromatography1976Journal of medicinal chemistry, Jul, Volume: 19, Issue:7
Potential histamine H2-receptor antagonists. 3. Methylhistamines.
AID1148742In vitro agonist activity at histamine H1 receptor in guinea pig ileum assessed as contractile response relative to histamine in presence of atropine1976Journal of medicinal chemistry, Jul, Volume: 19, Issue:7
Potential histamine H2-receptor antagonists. 3. Methylhistamines.
AID1148744In vivo agonist activity at histamine H2 receptor in iv dosed anesthetized rat assessed as stimulation of gastric acid secretion relative to histamine1976Journal of medicinal chemistry, Jul, Volume: 19, Issue:7
Potential histamine H2-receptor antagonists. 3. Methylhistamines.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID1148746In vivo antagonist activity at histamine H2 receptor in anesthetized rat assessed as inhibition of histamine-stimulated gastric acid secretion up to 256 umol/kg, iv1976Journal of medicinal chemistry, Jul, Volume: 19, Issue:7
Potential histamine H2-receptor antagonists. 3. Methylhistamines.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (152)

TimeframeStudies, This Drug (%)All Drugs %
pre-199045 (29.61)18.7374
1990's40 (26.32)18.2507
2000's36 (23.68)29.6817
2010's24 (15.79)24.3611
2020's7 (4.61)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 17.01

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index17.01 (24.57)
Research Supply Index5.02 (2.92)
Research Growth Index4.41 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (17.01)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (1.34%)5.53%
Trials0 (0.00%)5.53%
Reviews3 (2.01%)6.00%
Reviews0 (0.00%)6.00%
Case Studies1 (0.67%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other143 (95.97%)84.16%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]